Approval · Notice of Compliance 16350 · 2014

ELTROXIN: Notice of Compliance 16350

Issued November 24, 2014

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 16350
Date: November 24, 2014
Company: Aspri Pharma Canada Inc.Concord, Ontario, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Reason: Manufacturer name change
Therapeutic class: Thyroid hormone

Products in this notice

Brand	DIN	Status today
ELTROXIN	02213192	Marketed
ELTROXIN	02213206	Marketed
ELTROXIN	02213214	Marketed
ELTROXIN	02213222	Marketed
ELTROXIN	02213230	Cancelled Post Market

Medicinal ingredients

LEVOTHYROXINE SODIUM 50 MCG per TAB
LEVOTHYROXINE SODIUM 100 MCG per TAB
LEVOTHYROXINE SODIUM 150 MCG per TAB
LEVOTHYROXINE SODIUM 200 MCG per TAB
LEVOTHYROXINE SODIUM 300 MCG per TAB